Advertisement

Journal of Bioenergetics and Biomembranes

, Volume 44, Issue 1, pp 1–6 | Cite as

3-bromopyruvate (3BP) a fast acting, promising, powerful, specific, and effective “small molecule” anti-cancer agent taken from labside to bedside: introduction to a special issue

  • Peter L. Pedersen
Editorial

Abstract

Although the “Warburg effect”, i.e., elevated glucose metabolism to lactic acid (glycolysis) even in the presence of oxygen, has been recognized as the most common biochemical phenotype of cancer for over 80 years, its biochemical and genetic basis remained unknown for over 50 years. Work focused on elucidating the underlying mechanism(s) of the “Warburg effect” commenced in the author’s laboratory in 1969. By 1985 among the novel findings made two related most directly to the basis of the “Warburg effect”, the first that the mitochondrial content of tumors exhibiting this phenotype is markedly decreased relative to the tissue of origin, and the second that such mitochondria have markedly elevated amounts of the enzyme hexokinase-2 (HK2) bound to their outer membrane. HK2 is the first of a number of enzymes in cancer cells involved in metabolizing the sugar glucose to lactic acid. At its mitochondrial location HK2 binds at/near the protein VDAC (voltage dependent anion channel), escapes inhibition by its product glucose-6-phosphate, and gains access to mitochondrial produced ATP. As shown by others, it also helps immortalize cancer cells, i.e., prevents cell death. Based on these studies, the author’s laboratory commenced experiments to elucidate the gene basis for the overexpression of HK2 in cancer. These studies led to both the discovery of a unique HK2 promoter region markedly activated by both hypoxic conditions and moderately activated by several metabolites (e.g., glucose), Also discovered was the promoter’s regulation by epigenetic events (i.e., methylation, demethylation). Finally, the author’s laboratory turned to the most important objective. Could they selectively and completely destroy cancerous tumors in animals? This led to the discovery in an experiment conceived, designed, and conducted by Young Ko that the small molecule 3-bromopyruvate (3BP), the subject of this mini-review series, is an incredibly powerful and swift acting anticancer agent. Significantly, in subsequent experiments with rodents (19 animals with advanced cancer) Ko led a project in which 3BP was shown in a short treatment period to eradicate all (100%). Ko’s and co-author’s findings once published attracted global attention leading world-wide to many other studies and publications related to 3BP and its potent anti-cancer effect. This Issue of the Journal of Bioenergetics and Biomembranes (JOBB 44-1) captures only a sampling of research conducted to date on 3BP as an anticancer agent, and includes also a Case Report on the first human patient known to the author to be treated with specially formulated 3BP. Suffice it to say in this bottom line, “3BP, a small molecule, results in a remarkable therapeutic effect when it comes to treating cancers exhibiting a “Warburg effect”. This includes most cancer types.

Keywords

3-bromopyruvate (3BP) Cancer Glycolysis Mitochondria Warburg effect Hexokinase-2 (HK2)] 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Bustamante E, Pedersen PL (1977) Proc. Natl Acad Sci (USA) 74:3735–3739CrossRefGoogle Scholar
  2. Bustamante E, Morris HP, Pedersen PL (1981) J Biol Chem 256:8699–8704Google Scholar
  3. Cardaci S, Desideri E, Ciriolo R (2012) J Bioenerg Biomemb 44:17–29Google Scholar
  4. Davidescu M, Sciaccaluga M, Maccchioni L, Agelina R, Lopalco P, Rambotti MG, Roberti R, Corcelli A, Castigli E, Corazzi L (2012) J Bioenerg Biomemb 44:51–60Google Scholar
  5. El Sayed SM, Abou El-Magd RM, Shishido Y, Chung SP, Diem TH, Sakai T, Watanabe H Kagami S, Fukui K (2012) J Bioenerg Biomemb 44:51–60Google Scholar
  6. Gatenby RA, Gawlinski ET (2003) Cancer Res 63:3847–3854Google Scholar
  7. Goel A, Mathupala SP, Pedersen PL (2003) J Biol Chem 278:15333–15340CrossRefGoogle Scholar
  8. Hayat MJ, Howlader N, Reichman ME, Edwards BK (2007) Oncologist 12:20–37CrossRefGoogle Scholar
  9. Icard P, Zhang X-D, Lemoisson E., Louis M-H, Allouche S, Lincet H, Laurent P (2012) J Bioenerg Biomemb 44:81–90Google Scholar
  10. Kennedy EP, Lehninger AL (1949) Lehninger Al. J Biol Chem 179:957–972Google Scholar
  11. Ko YH, Geschwind JF, Pedersen PL (2001) Can Lett 173:83–91CrossRefGoogle Scholar
  12. Ko YH, Smith BL, Wang Y, Pomper MG, Rini DA, Torbenson MS, Hullihen J, Pedersen PL (2004) Biochem Biophys Res Commun 324:269–275CrossRefGoogle Scholar
  13. Ko YH, Verhoeven HA, Lee MJ, Corbin DJ, Vogl TJ, Pedersen PL (2012) J Bioenerg Biomemb 44:149–156Google Scholar
  14. Lee MG, Pedersen PL (2003) J Biol Chem: 278:41047–41058CrossRefGoogle Scholar
  15. Lis P, Zarzycki M, Ko YH, Casal M, Pedersen PL, Goffeau A, Ulaszewski S (2012) J Bioenerg Biomemb 44:141–147Google Scholar
  16. Mathupala SP, Rempel A, Pedersen PL (2001) J Biol Chem 276:43407–43412CrossRefGoogle Scholar
  17. Mathupala SP, Ko YH, Pedersen PL (2009) Semin Cancer Biol 19:17–24CrossRefGoogle Scholar
  18. Mathupala SP, Ko YH, Pedersen PL (2010) Biochim Biophys Acta 1797:1225–1230CrossRefGoogle Scholar
  19. Nakano A, Miki H, Nakamura S, Harada T, Oda A, Amou H, Fujii S, Kagawa K, Takeuchi K, Ozaki S, Matsumoto T, Abe M (2012) J Bioenerg Biomemb 44:31–38Google Scholar
  20. Nakashima RA, Mangan PS, Colombini M, Pedersen PL (1986) Biochemistry 25:1013–1021CrossRefGoogle Scholar
  21. Pastorino JB, Shulga N, Hoek JB (2002) J Biol Chem 277:7610–7618CrossRefGoogle Scholar
  22. Pedersen PL, Eska T, Morris HP (1971) Catterall WA. Proc Natl Acad Sci (USA) 68:1079–1082CrossRefGoogle Scholar
  23. Queiros O, Preto A, Pacheco A, Pinheiro C, Azevedo-Silva J, Moreira R, Pedro M., Ko YH, Pedersen P, Baltazar F, Casal M (2012) J Bioenerg Biomemb 44:127–139Google Scholar
  24. Rempel A, Mathupala SP, Griffin CA, Hawkins AL, Pedersen PL (1996) Cancer Res 56:2468–2471Google Scholar
  25. Robey RB, Hay N (2005) Hay N 4:654–658Google Scholar
  26. Rodrigues-Ferreira C, Pereira da Silva, Galina A (2012) J Bioenerg Biomemb 44:39–49Google Scholar
  27. Schreiber JR, Balcavage WX, Morris HP, Pedersen PL (1970) Cancer Res 30:2497–2501Google Scholar
  28. Shosan MC (2012) J Bioenerg Biomemb 44:7–15Google Scholar
  29. Tang Z, Yuan S, Hu Y, Zhang H, Wu W, Zeng Z, Yang J, Yun J, Xu R, Huang P (2012) J Bioenerg Biomemb 44:117–125Google Scholar
  30. Verhoeven HA,van Griensven LJLD (2012) J Bioenerg Biomemb 44:91–99Google Scholar
  31. Warburg O (1930) Metabolism of tumors. Arnold Constable, LondonGoogle Scholar
  32. Warburg O (1956) On the origin of cancer cells. Science 24:300–314Google Scholar
  33. Yu SJ, Yoon J-H, Yang J-I, Cho EJ, Kwak MS, Jang ES, Lee J-H, Kim YJ, Lee H-S, Kim CY (2012) J Bioenerg Biomemb 44:101–115Google Scholar

Copyright information

© Springer Science+Business Media, LLC 2012

Authors and Affiliations

  1. 1.Department of Biological Chemistry, Center for Cell Metabolism and Obesity Research, and Sidney Kimmel Cancer Center, School of MedicineJohns Hopkins UniversityBaltimoreUSA
  2. 2.Department of Biological Chemistry, School of MedicineJohns Hopkins UniversityBaltimoreUSA

Personalised recommendations